Designing IND-Enabling Toxicity Studies For Complex Drug Modalities

Altasciences is at the forefront of designing studies for new drug modalities and adapting traditional small molecule IND-enabling studies to meet the evolving needs of the pharmaceutical industry. This webinar, supported by case studies, explores recommended study designs that align with regulatory requirements, best practices for species selection, and methods employed by Altasciences to optimize the use of research animals while adhering to the principles of the 3Rs (Replacement, Reduction, and Refinement).

Important topics covered include:

1. Modified study designs to address the needs of today’s new drug modalities for a better chance at regulatory acceptance.
2. Selecting the right species for your program while adhering to the principles of the 3Rs.
3. How your CRO’s program management team can facilitate quick decision-making and optimal reporting timelines for your crucial IND-enabling studies.